Enable JavaScript to visit this website.

ASPIRE-Hemophilia Apply


To be eligible for an ASPIRE Hemophilia Research Award, applicants must:
  • have a doctoral degree (MD, PhD, PharmD, or physiotherapy, social work, or advanced nursing degree), and
  • reside and practice in the United States.


  • Applications must be received by Friday, April 13, 2018, 11:59 p.m. Eastern Time
  • Addenda, supplemental materials, changes, or updates will not be accepted after the deadline
  • Award decisions will be made and applicants will be notified by June 29, 2018
  • The final study report or an interim progress report (dependent on whether a one- or two-year Award is granted) will be expected on or before December 31, 2019

How to Apply

Applications should be submitted through Pfizer’s INSPIIRE website see the link below)., Register at the top right of the page then follow the online instructions for ASPIRE. Be sure to answer yes to the first question "Are applying for a competitive grant". You will then see a listing of all current competitive grants available and you may select the 2018 ASPIRE Hemophilia Awards, United States from the competitive program dropdown.

Completed application forms must be accompanied by the following documents:

  • Cover letter on institutional letterhead
  • Relevant articles from the applicant’s scientific publications (if applicable)
  • Description of preliminary work in proposed research topic
  • An abbreviated curriculum vitae (CV) (limited to 3 pages); NIH biosketch format will be accepted
  • Description of available research facilities
  • Listing of other research support with a description of overlap with ASPIRE application, if any, and, if applicable, a listing of proposed collaborators (including CVs)
  • Bibliography of relevant references
  • Itemized budget for proposed research

Click Here to Apply for a 2018 ASPIRE United States Hemophilia Research Award and Access the INSPIIRE site.


Please see the Frequently Asked Questions (FAQ) page for help.

You may also e-mail questions to [email protected]